２例の肝細胞癌患者に対して経肝動脈的に投与されたＬｙｍｐｈｏｋｉｎｅ　ａｃｔｉｖａｔｅｄ　ｋｉｌｌｅｒ（ＬＡＫ）細胞とＩｎｔｅｒｌｅｕｋｉｎ‐２（ＩＬ‐２）の臨床効果

DOI Web Site

書誌事項

タイトル別名
  • Clinical trial of trans-arterial administration of LAK and IL-2 to patient with hepatocellural carcinoma - Case reports.

この論文をさがす

抄録

Two HCC (hepatocellural carcinoma) were treated by newly established immuno-therapy. Peripheral blood lymphocytes from these patients were cultivated in vitro under the presence of recombinant IL-2, washed and injected with IL-2 into the hepatic artery via previously detained catheter at once a week. A significant reduction of serum alpha-fetoprotein (AFP) level was observed in these two patients. The study of case 2 who had been treated by relatively large amount of lymphocytes and 8 times of injections of LAK revealed that with reduction of AFP lebel, her main tumor which was 3.0×3.5cm before the treatments was hard to identified after the treatment by CT scanner, No major side effect was found in these patients after the administration of LAK and IL-2. Thus, these results suggest that this new immuno-therapy is one of effective medications to HCC patients.

収録刊行物

  • 肝臓

    肝臓 28 (4), 477-482, 1987

    一般社団法人　日本肝臓学会

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ